Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
NCT04108858 · National Cancer Institute (NCI) · PHASE1/PHASE2 · terminated · last registry update 2025-10-01 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Inadequate accrual rate” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3CA in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-10Also stopped (terminated): Novartis Pharmaceuticals, alpelisib + placebo (NCT04251533)
- 2026-07-10Results posted on the registry: Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-10Also stopped (terminated): Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-07Results posted on the registry: M.D. Anderson Cancer Center, Alpelisib + Nab-paclitaxel (NCT04216472)
- 2026-07-07Also stopped (terminated): M.D. Anderson Cancer Center, Alpelisib + Nab-paclitaxel (NCT04216472)
- 2026-06-25Results posted on the registry: Novartis Pharmaceuticals, Alpelisib + Fulvestrant (NCT05631795)
- 2026-04-21Also stopped (terminated): Institut Paoli-Calmettes, BKM120 + lapatinib (NCT01589861)
- 2026-01-22Results posted on the registry: Jennifer Lee Caswell-Jin, Alpelisib + Tamoxifen (NCT05101564)
- 2025-11-24Results posted on the registry: Sanofi, Amcenestrant + Palbociclib (NCT03284957)
- 2025-11-24Also stopped (terminated): Sanofi, Amcenestrant + Palbociclib (NCT03284957)
- 2025-07-28Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Eribulin Mesylate (NCT04345913)
- 2025-07-22Also stopped (terminated): Cancer Trials Ireland, Copanlisib + Trastuzumab emtansine (NCT04042051)
- 2025-05-31Results posted on the registry: Bryan Schneider, MD, Capecitabine + Talazoparib (NCT04849364)
- 2025-05-31Also stopped (terminated): Bryan Schneider, MD, Capecitabine + Talazoparib (NCT04849364)
- 2025-05-26Also stopped (terminated): Mayo Clinic, Belinostat + Carfilzomib (NCT03432741)
- 2025-04-10Results posted on the registry: Inova Health Care Services, Biopsy-Guided Therapy Selection (NCT04965688)
- 2025-04-10Also stopped (terminated): Inova Health Care Services, Biopsy-Guided Therapy Selection (NCT04965688)
- 2025-01-24Phase 3 first posted: Hoffmann-La Roche, Inavolisib + Placebo (NCT06790693)
- 2025-01-03Phase 3 first posted: Celcuity Inc, Arm A: Gedatolisib + Palbociclib + Fulvestrant + Arm B: Ribociclib + Fulvestrant (NCT06757634)
- 2024-12-09Results posted on the registry: Memorial Sloan Kettering Cancer Center, BYL719 + Letrozole (NCT01870505)
- 2024-10-09Results posted on the registry: Hoffmann-La Roche, Inavolisib + Placebo (NCT04191499)
- 2024-10-09Also stopped (terminated): Novartis Pharmaceuticals, Alpelisib + Fulvestrant (NCT04899349)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision